In view of these significant results, compound 5d, which combines both α-glucosidase and DPP-4 inhibitory activities, presents great potential as a lead compound for the development of a novel dual inhibitor treatment strategy for type 2 diabetes. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.